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The changing patterns of chronic kidney disease: The need
to develop strategies for prevention relevant to different
regions and countries. Chronic diseases are now in pandemic
proportions and are the major cause of morbidity and mortal-
ity worldwide. Long-term predictions show that the burden will
fall increasingly on developing countries. Type II diabetes is
now the major global cause of chronic kidney disease. How-
ever, chronic kidney disease should not be viewed in isola-
tion, because it is also a major risk factor for cardiovascular
deaths.
It is both a medical and economic imperative to introduce
screening and management programs for chronic kidney dis-
ease, diabetes, hypertension, and cardiovascular disease world-
wide but particularly in the emerging world. Such programs
should be tailored to the needs of the individual country, in-
volve local health providers, be assessable as to their efficacy,
and become self-sufficient within 5 years.
Chronic diseases are now in pandemic proportions and
are the major causes of morbidity and mortality world-
wide [1, 2]. The World Health Organization (WHO) es-
timated that in 2003, of 56 million global deaths, 60%
were due to chronic disease. The global prevalence of
chronic disease is rapidly increasing, particularly in the
developing world, mainly due to the changing pattern of
disease from infectious to chronic diseases following eco-
nomic development and industrialization. According to
data from a recent WHO report [3], in the world’s most
populous country, China, the age-specific death rate from
cardiovascular disease has increased 100% to 300% over
the last 2 decades. India, the second most populous coun-
try, has the highest number of patients with diabetes in
the world, and annual coronary deaths are expected to
reach 2 million by 2010. The global number of individu-
als with diabetes in 2000 was estimated to be 171 million,
and projected to 366 million in 2030 [4]. The estimated
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global dialysis population for end-stage chronic kidney
disease is over 1.1 million and will be 2 million by the
year 2010 [5], expanding at a rate of 7% per year, with
an aggregate cost of more than US $1 trillion [6]. In de-
veloping and developed countries, chronic disease is now
the principle cause of disability and the greatest user of
health resources. The overall cost of chronic disease is so
profound that it will reduce productivity and significantly
reduce economic growth in individual countries and re-
gions, especially in the developing world. Long-term pre-
dictions show that the burden will increasingly fall on
developing countries. Already, 72% of deaths from all
chronic diseases occur in low and middle income coun-
tries. Mortality from ischemic heart disease and stroke
will nearly triple in Latin America, the Middle East, and
sub-Saharan Africa [3]. Thus, the major impact of the
epidemic of chronic disease will be in emerging coun-
tries. However, universities and their teaching programs,
as well as policy makers, health providers, aid organiza-
tions (nongovernmental organizations), and academics,
have paid scant attention to this problem and its preven-
tion.
As a consequence of this changing disease profile from
infectious to chronic diseases, we are now experiencing a
change in the cause of end-stage kidney disease. Type II
diabetes is now the major cause of end-stage renal fail-
ure worldwide, both in the developed and the emerging
world. Thus, type II diabetes, potentially a preventable
disease, now causes more end-stage renal disease glob-
ally than glomerulonephritis.
What can be done to address this problem of an inex-
orable increase in chronic diseases and their enormous
global medical and economic implications? The diabetes
pandemic must be recognized by health providers as a
major health threat of the 21st century [7]. The statistics
are stark. Paradoxically, the predominant increase will be
in the emerging world, where those least able to afford
and cope with the problem will be affected. There will be
an 88% increase in the number of people with diabetes
in Latin America, a 98% increase in Africa, and a 91%
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increase in Asia over the next 25 years. This compares
with an estimated increase of 18% in Europe and 59% in
the United States.
Diabetes affected 2.8% of the global population in
2000, and this will triple to 6.8% by 2030. By 2030, 81%
of those with diabetes will live in the developing world,
almost 3 times the rate of increase compared with de-
veloped countries. WHO has estimated that the cost of
diabetic care accounts for 2.5% to 15% of national health
care budgets. The global cost, now about US $150 billion,
will double by 2005. Countries with a high prevalence
of diabetes may be spending up to 40% of their health
care budget on diabetes and its complications [3]. Dia-
betes is not only a risk factor for chronic kidney disease
but also for cardiovascular disease, and the majority of
diabetic patients with kidney disease die from myocar-
dial infarction or a stroke before reaching end-stage renal
failure.
About 40% of patients with type II diabetes have
chronic kidney disease reflected initially by microal-
buminuria. Microalbuminuria is a very powerful inde-
pendent risk factor for progression of chronic kidney
disease and also for the risk of cardiovascular death.
Thus, it is very important to screen patients with dia-
betes and hypertension for microalbuminuria. These 2
conditions account for about three fourths of the 6% of
people in the community with microalbuminuria [8,9].
Treatment with either angiotensin-converting enzyme in-
hibition or angiotensin receptor blockade can reduce al-
buminuria/proteinuria and reduce the risk of progression
to kidney disease and cardiovascular complications [10,
11]. Thus, there is a strong case for screening the com-
munity for early detection of hypertension, diabetes, and
chronic kidney disease in an attempt to treat and slow the
progression of chronic kidney disease and its cardiovas-
cular complications.
Chronic kidney disease should not be viewed in
isolation. Chronic kidney disease has a complex inter-
relationship with cardiovascular disease, diabetes, and
hypertension. Indeed, chronic kidney disease is a major
risk factor for cardiovascular disease. There is a graded
inverse relationship between initial renal function and
subsequent risk of death and complications from car-
diovascular disease [12]. Similarly, diabetes and glucose
intolerance are also risk factors for renal disease and car-
diovascular disease. Albuminuria is not only a risk fac-
tor for progression of renal disease but, in addition, for
cardiovascular events in patients with diabetes or kid-
ney disease and also people in the general community
[13, 14].
Therefore, it is imperative for screening and preven-
tion programs to detect and then treat people with not
only kidney disease per se but also those with diabetes,
hypertension, and cardiovascular disease as well. Overall
risk factors such as lifestyle, diet, inactivity, smoking, and
alcohol must be addressed, and individual and commu-
nity educational programs must be an integral part of the
overall management plan.
Obviously the first requirement, apart from establish-
ing disease prevalence in the community, is to try and
prevent the occurrence of diabetic nephropathy itself by
preventing the onset of diabetes. There have been sev-
eral recent studies demonstrating that lifestyle changes
involving diet and exercise can reduce the rate of pro-
gression from glucose intolerance to diabetes [15]. Thus,
public education and awareness of the perils of globaliza-
tion become a management imperative particularly in the
emerging world. Again, politicians and health providers
must be made keenly aware of the problem and the need
for urgent action.
The second requirement is the need to introduce
“detection and prevention” programs in the emerging
world, each tailored to local requirements. These pro-
grams will involve the training of local experts, sustain-
ing the management plan and evaluation of the outcome.
This also requires partnerships with the local community,
health caregivers, governments, nongovernmental orga-
nizations, and probably the pharmaceutical industry.
One of the International Society of Nephrology’s (ISN)
strategies under the ISN- Commission for the Global
Advancement of Nephrology Research Committee is to
develop guidelines which can be used as a basis for such
detection and prevention programs throughout the world
but particularly in the developing countries, where the
greatest burden of chronic disease is falling.
The overall aim is to detect chronic disease—diabetes,
chronic kidney disease, hypertension, and cardiovascu-
lar disease—and to retard or prevent its progression
with effective treatment. This involves community ed-
ucation, prevention of disease by lifestyle modifications,
early detection of disease, and treatment of established
disease.
There are several basic axioms which will be followed
in developing these guidelines. (1) The screening and
treatment programs should be similar for all countries
but flexible enough to be tailored to individual country’s
conditions and requirements. (2) The programs should
include data collection modules to provide some basic
epidemiologic data to help assess efficacy, to allow com-
parisons between countries, and to provide adequate
follow-up. (3) Different frameworks will be needed for
low, middle, and high income countries and for individual
circumstances. (4) The programs should encompass not
only chronic kidney disease but hypertension, diabetes,
and cardiovascular disease. (5) The screening should be
as widespread as possible and provide adequate follow-
up. (6) Treatment should be provided for people who
require it. (7) A data management program will be devel-
oped in Bergamo, Italy, to allow for epidemiologic evalua-
tion of basic clinical data (nonidentifiable). (8) Programs
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will be undertaken with varying partners, such as local
health providers, nongovernmental organizations, other
professional bodies, or regional or international organiza-
tions and industry, dependent on local needs. (9) Funding
will usually require a mix of local health providers, gov-
ernments, nongovernmental organizations, philanthropic
organizations, and industry. (10) The program must be
sustainable. Local input and expertise are essential, and
self-sufficiency should be reached after 5 years.
CONCLUSION
Development of this practical and feasible program
will require an enormous amount of commitment from
everyone concerned and the cooperation of a large num-
ber of both local and global participants. The ISN will
play a facilitating role wherever feasible.
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